Amgen Reports Strong Growth in Second Quarter 2024
Strong Financial Performance
Amgen reported a strong second quarter of 2024, with financial results that exceeded expectations. Total revenues for the quarter reached $33.5 billion, representing an increase of 10% compared to the same period in 2023. This growth was driven by strong demand for the company's biologics, including Enbrel, Neulasta, and Prolia.
Financial Highlights
Key financial highlights for the second quarter include:
- Total revenues of $33.5 billion, up 10% from Q2 2023
- Net income of $8.2 billion, up 12% from Q2 2023
- Diluted EPS of $3.40, up 14% from Q2 2023
Amgen's strong financial performance in the second quarter reinforces the company's position as a leader in the biotechnology industry. The company's diverse portfolio of innovative medicines and its continued investment in research and development position it well for continued growth in the future.
Comments